Milnacipran Hydrochloride
| Purity | Grade | Package | Stock | Price | Quantity |
|---|---|---|---|---|---|
| 98% | RG | 100MG | In Stock | 13 USD | |
| 98% | RG | 250MG | In Stock | 18 USD | |
| 98% | RG | 1G | In Stock | 42 USD | |
| 98% | RG | 25G | In Stock | 525 USD | |
|
Should you have any questions, please contact us by Email. |
|||||
Biological Activity of 101152-94-7
Milnacipran exhibits significant biological activity as an SNRI. By inhibiting the reuptake of serotonin and norepinephrine, it increases the availability of these neurotransmitters in the synaptic cleft, which is essential for mood regulation and pain perception. Clinical studies have demonstrated its efficacy in reducing depressive symptoms and improving functional outcomes in patients with fibromyalgia . Additionally, recent research suggests that one of its enantiomers, levomilnacipran, may have potential applications in treating Alzheimer's disease by inhibiting beta-site amyloid precursor protein cleaving enzyme-1 .
NMR spectrum of 101152-94-7
Safety Information of 101152-94-7
Download COA of 101152-94-7
Bulk Packaging Price Explanation of 101152-94-7
Please email your required order quantity and detailed technical specifications to sales@.
Our sales team will promptly prepare an accurate quotation for your bulk order and provide a comprehensive pricing proposal.
Purchase Instructions of 101152-94-7
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


